VA20 Stock Overview
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Vapotherm, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.98 |
| 52 Week High | US$20.96 |
| 52 Week Low | US$2.21 |
| Beta | -1.14 |
| 1 Month Change | 0% |
| 3 Month Change | -2.62% |
| 1 Year Change | -72.44% |
| 3 Year Change | -98.37% |
| 5 Year Change | -97.38% |
| Change since IPO | -97.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| VA20 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -5.1% | -1.5% |
| 1Y | -72.4% | -9.0% | 0.9% |
Return vs Industry: VA20 underperformed the German Medical Equipment industry which returned -2.5% over the past year.
Return vs Market: VA20 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| VA20 volatility | |
|---|---|
| VA20 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: VA20's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine VA20's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 261 | Joe Army | www.vapotherm.com |
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to treat patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol medication; and tracheostomy adaptors.
Vapotherm, Inc. Fundamentals Summary
| VA20 fundamental statistics | |
|---|---|
| Market cap | €14.51m |
| Earnings (TTM) | -€64.89m |
| Revenue (TTM) | €63.16m |
0.2x
P/S Ratio-0.2x
P/E RatioIs VA20 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VA20 income statement (TTM) | |
|---|---|
| Revenue | US$67.60m |
| Cost of Revenue | US$43.23m |
| Gross Profit | US$24.36m |
| Other Expenses | US$93.81m |
| Earnings | -US$69.44m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.31 |
| Gross Margin | 36.04% |
| Net Profit Margin | -102.73% |
| Debt/Equity Ratio | -219.9% |
How did VA20 perform over the long term?
See historical performance and comparison